

**Supplemental Table 1. *Tsc2*<sup>+/-</sup> extra-renal tumorigenesis is HMGA2 dependent.**

	Tsc2 <sup>+/-</sup> -Hmga2 <sup>+/+</sup> and Tsc2 <sup>+/-</sup> -Hmga2 <sup>+/-</sup> (n=227)					Tsc2 <sup>+/-</sup> -Hmga2 <sup>-/-</sup> (n=19)				
Origin Of Tumor	A2	BP2	Tuberin	pmTOR	pS6K	A2	BP2	Tuberin	pmTOR	pS6K
Kidney	100	100	86	30	30	0	0	81	31	31
Lung	100	100	100	0	0					
Liver	100	100	100	0	0			No Tumors		
ExH	100	100	100	0	0					

Summary of IHC analysis of HMGA2 (A2), IGF2BP2 (BP2), tuberin, pho-mTOR (pmTOR) and pho-p70 S6 kinase (pS6K) of tumors from *Tsc2*<sup>+/-</sup> mice. Data are presented as the percentage of samples that stained positive for each antibody and n denotes number of tumors analyzed.

**Supplemental Table 2. Summary of human AML LOH analysis.**

Patient	Tumor	Tuberin	Marker Positive
16	AML	+	No LOH
17	AML	-	D16S525, D16S283
18	AML	+	No LOH
19	AML	+	No LOH
20	AML	-	D16S283
21	AML	-	D16S283, D16S291
23	AML	+	No LOH
24	AML	+	No LOH
26	AML	+	No LOH
9019	AML	+	No LOH
9029	AML	+	No LOH
9040	AML	-	D16S283

*TSC2* LOH was examined for individual markers (Kg8, D16S525, D16S283 and D16S291) on chromosome 16p13 from 12 AML samples, with only tuberin negative samples having *TSC2* LOH.